Dalteparin (Fragmin, Pfizer) for the extended treatment of symptomatic venous thromboembolism (proximal deep vein thrombosis and/or pulmonary embolus) to prevent recurrent venous thromboembolism in patients with cancer
Recommendations for approval
Recommendations against approval
Nonapprovable designations
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More